No AstraZeneca-Bristol Myers Deal: Senior Source Reveals
📊 AZN — Piyasa Yorumu
▼ down · 60%The news confirms that an anticipated deal between AstraZeneca and Bristol Myers is not happening, which could disappoint the market. The stock has fallen 5.16% in the last 24 hours, indicating increased selling pressure. Although the RSI is neutral at 52, the MACD is negative and below the signal line, suggesting weak momentum. The price is above the SMA20 but below the SMA50, making the short-term outlook uncertain. The lack of a deal announcement could increase the risk of further downside in the near term.
📊 BMY — Piyasa Yorumu
▼ down · 60%The news headline indicates that there is no expected deal between AstraZeneca and Bristol Myers, which could disappoint the market and put pressure on the stock. Technical indicators also point to weakness: RSI is at 42, in the neutral-to-low zone, and the price is below both the 20-day and 50-day moving averages. MACD is below the signal line, and negative momentum continues. A 1.9% decline in the last 24 hours shows increasing selling pressure. In the short term, this negative news and technical outlook could lead to further declines in the stock.